Premium
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis
Author(s) -
Perumpail R.B.,
Wong R.J.,
Ha L.D.,
Pham E.A.,
Wang U.,
Luong H.,
Kumari R.,
Daugherty T.J.,
Higgins J.P.,
Younossi Z.M.,
Kim W.R.,
Glenn J.S.,
Ahmed A.
Publication year - 2015
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12348
Subject(s) - medicine , simeprevir , sofosbuvir , tolerability , ribavirin , pegylated interferon , immunosuppression , population , transplantation , tacrolimus , hepatitis c , combination therapy , hepatitis c virus , pharmacology , gastroenterology , virology , adverse effect , virus , environmental health
We report safety, tolerability, and 12‐week sustained virologic response with half‐standard dose sofosbuvir and standard‐dose simeprevir combination therapy in a hepatitis C virus genotype 1a‐infected liver transplant recipient on hemodialysis – uncharted territory for sofosbuvir‐based therapy. The patient was a non‐responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill‐splitting and administration of half‐standard dose, 200 mg per day. No drug–drug interactions were noted with tacrolimus‐based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.